CDH26 Antibody

What is CDH26 and what cellular functions does it regulate?

CDH26 (Cadherin-26) is a member of the cadherin superfamily that mediates diverse processes critical in inflammation, including cell adhesion, migration, and differentiation. Research indicates that CDH26 plays a crucial role in allergic inflammatory responses by regulating IL-4 receptor (IL-4R)-mediated signaling. Unlike traditional cadherins, CDH26 has specialized functions in epithelial cells and immune cells, particularly macrophages .

In macrophages, CDH26 amplifies IL-4R signaling by interacting with STUB1 and suppressing STUB1-mediated IL-4Rα ubiquitination and proteasomal degradation. This mechanism promotes alternative activation of macrophages, which drives type 2 airway inflammation in conditions like asthma . Additionally, CDH26 serves as an alpha integrin-binding epithelial receptor, suggesting it plays a role in epithelial-immune cell interactions during inflammatory responses .

What are the known isoforms of CDH26 and their structural differences?

Two main transcript variants of CDH26 have been identified through sequencing analysis:

• CDH26 variant A (NM_177980): Contains 3192 base pairs across 18 exons with a predicted protein molecular weight of 92.4 kDa

• CDH26 variant B (NM_021810): Contains 1092 base pairs across 6 exons with a predicted protein molecular weight of 17.7 kDa

Protein modeling of variant A predicts four cadherin domains, a transmembrane region, and a cytoplasmic domain. In contrast, variant B has a structure similar to the cytoplasmic domain of variant A but lacks a transmembrane region, suggesting potentially different cellular functions and localizations . This structural difference has important implications for antibody selection, as antibodies targeting different domains may yield varying results depending on the experimental context.

What is the tissue distribution pattern of CDH26 in normal and disease states?

CDH26 shows distinct tissue distribution patterns that vary between normal and disease states:

In normal tissues:

• Low baseline expression in airway epithelial cells

• Limited expression in esophageal epithelial cells, primarily confined to surface epithelial cells

• Minimal expression in gastric epithelial cells

In allergic inflammatory conditions:

• Significantly upregulated in lung macrophages from patients with eosinophilic asthma

• Increased expression in bronchoalveolar lavage (BAL) cells from asthma patients, particularly in those with eosinophilic asthma

• Enhanced expression in epithelial cells of allergic gastrointestinal tissues, including both surface and gland epithelial cells in eosinophilic gastritis

• In eosinophilic esophagitis, expression extends to both surface epithelial cells and epithelial cells in the expanded basal layer

Importantly, CDH26 expression correlates with markers of allergic inflammation, including fractional exhaled nitric oxide (FeNO), sputum eosinophil percentages, and serum IgE levels, suggesting its potential utility as a biomarker for allergic diseases .

What types of CDH26 antibodies are available for research applications?

Multiple CDH26 antibodies are available for research, targeting different epitopes and offering various applications:

Additionally, these antibodies come in various conjugated forms:

• Unconjugated for flexible detection methods

• HRP-conjugated for direct enzymatic detection

• FITC-conjugated for direct fluorescence detection

• Biotin-conjugated for avidin-based detection systems

The diversity of available antibodies allows researchers to select the most appropriate tool based on their specific experimental requirements and the CDH26 domain of interest.

What experimental techniques are most effective for detecting CDH26 expression?

Several techniques have proven effective for CDH26 detection, each with specific applications:

• Western Blotting (WB):

  • Optimal for quantifying protein expression levels

  • Recommended antibody dilutions: 1:1000-3000

  • Can distinguish between variant A (92.4 kDa) and variant B (17.7 kDa)

  • Particularly effective for comparing expression levels between normal and disease states

• Immunofluorescence (IF) and Immunocytochemistry (ICC):

  • Ideal for cellular localization studies

  • Recommended antibody dilutions: 1:100-1:500

  • Enables co-localization studies with other markers (e.g., CD68 for macrophages)

  • Allows visualization of subcellular distribution

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Suitable for quantitative analysis of CDH26 in biological samples

  • Recommended antibody dilutions for peptide ELISA: 1:20000-1:40000

  • Provides high sensitivity for detecting low abundance proteins

• Immunohistochemistry (IHC):

  • Effective for tissue localization studies

  • Enables visualization of CDH26 distribution in intact tissues

  • Particularly valuable for comparing expression patterns between normal and diseased tissues

• Flow Cytometry:

  • Useful for identifying and quantifying CDH26-expressing cell populations

  • Enables multi-parameter analysis to correlate CDH26 expression with cell type markers

  • Can distinguish between surface and intracellular expression depending on antibody selection

What are the critical considerations for validating CDH26 antibody specificity?

Proper validation of CDH26 antibody specificity is essential for generating reliable research data:

• Positive and negative controls:

  • Positive controls: Use tissues known to express CDH26, such as BAL cells from eosinophilic asthma patients or epithelial cells from allergic gastrointestinal tissues

  • Negative controls: Include isotype-matched control antibodies and tissues with minimal CDH26 expression

• Isoform considerations:

  • Verify antibody specificity for variant A (92.4 kDa) versus variant B (17.7 kDa)

  • Consider using recombinant proteins of specific variants as positive controls

  • Select antibodies targeting the appropriate domain based on research questions

• Technical validation approaches:

  • Peptide competition assays to confirm binding specificity

  • siRNA knockdown experiments to verify signal reduction

  • Western blotting to confirm expected molecular weight

  • Immunoprecipitation followed by mass spectrometry for definitive identification

• Application-specific validation:

  • For IHC/IF: Include appropriate blocking steps to reduce background

  • For Western blotting: Verify antibody recognizes denatured protein at correct molecular weight

  • For flow cytometry: Include fluorescence-minus-one (FMO) controls

How should researchers design experiments to study CDH26 function in allergic inflammation?

Designing robust experiments to investigate CDH26 in allergic inflammation requires careful consideration of models and analytical approaches:

• In vitro models:

  • Primary human bronchial epithelial cells cultured at air-liquid interface (ALI)

  • Human macrophage cultures (monocyte-derived or alveolar macrophages from BAL)

  • Co-culture systems to investigate epithelial-macrophage interactions

  • CDH26 knockdown or overexpression systems to assess functional consequences

• In vivo models:

  • Ovalbumin-sensitized and challenged mouse models of allergic airway inflammation

  • Macrophage-specific CDH26 deletion using Cdh26^fl/fl^Lyz2Cre mice

  • Therapeutic intervention studies using CDH26 siRNA encapsulated lipid nanoparticles

• Human studies:

  • Collection of BAL cells, sputum, and tissue biopsies from patients with allergic conditions

  • Correlation of CDH26 expression with clinical parameters (FeNO, sputum eosinophils, serum IgE)

  • Comparison between different phenotypes (e.g., eosinophilic vs. non-eosinophilic asthma)

• Analytical approaches:

  • Gene expression analysis (qPCR for transcript levels)

  • Protein expression analysis (Western blotting, immunofluorescence)

  • Functional assays (IL-4R signaling, macrophage activation markers)

  • Signaling pathway analysis (ubiquitination assays, proteasomal degradation studies)

What methodology should be used to investigate CDH26's role in IL-4R signaling?

Investigating the role of CDH26 in IL-4R signaling requires specialized methodological approaches:

• Protein-protein interaction studies:

  • Co-immunoprecipitation to detect interactions between CDH26, STUB1, and IL-4Rα

  • Proximity ligation assay to visualize protein interactions in situ

  • Mass spectrometry analysis of CDH26 immunoprecipitates to identify novel interaction partners

• Ubiquitination and degradation assays:

  • IL-4Rα degradation assays in cells with CDH26 knockdown or overexpression

  • Ubiquitination assays to assess IL-4Rα ubiquitination levels

  • Proteasome inhibitor studies to confirm the role of proteasomal degradation

  • Pulse-chase experiments to measure IL-4Rα protein stability

• Signal transduction analysis:

  • Assessment of STAT6 phosphorylation as a downstream marker of IL-4R activation

  • Expression analysis of M2 macrophage markers (CD206, FIZZ1, CCL17)

  • Cytokine profiling to evaluate functional consequences of altered IL-4R signaling

  • Transcriptome analysis to identify affected gene networks

• Structure-function analysis:

  • Domain deletion experiments to identify critical regions of CDH26 for STUB1 interaction

  • Site-directed mutagenesis to identify key amino acid residues involved in protein interactions

  • Complementation studies with variant A versus variant B to assess isoform-specific effects

What are the optimal protocols for detecting CDH26 in tissue samples using immunostaining?

Optimized immunostaining protocols for CDH26 detection in various tissues:

• Lung tissue protocol:

  • Fixation: 4% paraformaldehyde for 24 hours

  • Sectioning: 5-6 μm thickness paraffin sections

  • Antigen retrieval: Citrate buffer (pH 6.0) at 95°C for 20 minutes

  • Blocking: 5% normal serum in PBS with 0.1% Triton X-100 for 1 hour

  • Primary antibody: CDH26 antibody (1:100-1:500) overnight at 4°C

  • Detection: Appropriate secondary antibody system based on primary antibody host

  • For co-localization: Include CD68 antibody for macrophage identification

• Gastrointestinal tissue protocol:

  • Similar fixation and processing as lung tissue

  • Extra washing steps for mucus-rich areas

  • For epithelial localization: Include epithelial markers for co-staining

  • Special attention to different compartments (surface vs. glandular regions)

• Cell-specific detection considerations:

  • For macrophages: Co-stain with CD68, assess morphology (enlarged foamy morphology in activated state)

  • For epithelial cells: Distinguish between surface localization and expression in the expanded basal layer

  • For co-localization studies: Use sequential staining approaches to avoid cross-reactivity

• Controls and validation:

  • Include isotype controls matched to primary antibody

  • Use known positive tissue (asthmatic lung, allergic GI tissue)

  • Include peptide blocking controls to confirm specificity

  • Quantify staining intensity using standardized imaging parameters

How should researchers quantify and analyze CDH26 expression data?

Quantitative analysis of CDH26 expression requires standardized approaches across different techniques:

• Transcript level analysis (qPCR):

  • Design primers specific for CDH26 variant A and variant B

  • Normalize to appropriate reference genes (GAPDH, β-actin, or 18S rRNA)

  • Use the 2^(-ΔΔCT) method for relative quantification

  • Report fold-change relative to appropriate controls

• Protein expression analysis (Western blot):

  • Include molecular weight markers to confirm band identity

  • Use appropriate loading controls (β-actin, GAPDH)

  • Perform densitometric analysis using software like ImageJ

  • Normalize band intensity to loading control

  • Present data as fold-change relative to control samples

• Immunofluorescence quantification:

  • Capture images under consistent exposure settings

  • Define regions of interest (ROIs) for standardized measurements

  • Measure mean fluorescence intensity within ROIs

  • Subtract background fluorescence

  • Report intensity values normalized to cell number or area

  • For co-localization, calculate Pearson's correlation coefficient

• Flow cytometry analysis:

  • Define positive populations using appropriate controls

  • Report both percentage of positive cells and mean fluorescence intensity

  • For heterogeneous samples, analyze CDH26 expression within defined cell populations

  • Consider multiparameter analysis to correlate with activation markers

What are common challenges in CDH26 detection and how can they be overcome?

Common technical challenges and solutions in CDH26 detection:

• Western blotting challenges:

  • Multiple bands or unexpected molecular weight:

    • Verify antibody specificity against recombinant proteins

    • Consider presence of different isoforms (variant A: 92.4 kDa, variant B: 17.7 kDa)

    • Check for potential post-translational modifications

  • Weak or no signal:

    • Increase protein loading (50-75 μg)

    • Optimize antibody concentration (1:1000-1:3000)

    • Extend primary antibody incubation (overnight at 4°C)

    • Use enhanced chemiluminescence detection

• Immunostaining challenges:

  • High background:

    • Increase blocking time or concentration

    • Add additional washing steps

    • Reduce secondary antibody concentration

    • Use more specific detection systems

  • Inconsistent staining:

    • Standardize fixation protocols

    • Optimize antigen retrieval conditions

    • Use positive control tissues in each experiment

• Cell-specific detection issues:

  • Macrophage identification:

    • Include CD68 or other macrophage markers in co-staining

    • Consider morphological characteristics (enlarged, foamy appearance in activated state)

  • Epithelial cell detection:

    • Use epithelial markers to confirm cell identity

    • Note differences in distribution patterns between normal and inflamed tissues

How should researchers interpret CDH26 expression in relation to allergic inflammation?

Interpreting CDH26 expression data in the context of allergic inflammation:

• Clinical correlations:

  • Examine relationships between CDH26 expression and clinical parameters:

    • Fractional exhaled nitric oxide (FeNO)

    • Sputum eosinophil percentages

    • Serum IgE levels

    • Disease severity metrics

• Cellular context considerations:

  • In macrophages:

    • Correlate with markers of alternative activation (CD206, FIZZ1, CCL17)

    • Consider relationship to IL-4Rα expression levels

    • Assess impact on macrophage functional responses

  • In epithelial cells:

    • Evaluate relationship to epithelial barrier function

    • Consider interactions with immune cells

• Mechanistic interpretations:

  • Assess impact on IL-4R signaling pathway:

    • STAT6 phosphorylation

    • Expression of downstream target genes

    • Functional consequences for type 2 inflammation

  • Consider role in protein-protein interactions:

    • CDH26-STUB1 interaction

    • Effect on IL-4Rα ubiquitination and degradation

    • Impact on receptor expression and signaling

• Therapeutic implications:

  • Evaluate CDH26 as a potential therapeutic target:

    • Effect of CDH26 targeting on airway inflammation

    • Impact on macrophage alternative activation

    • Potential for alleviating allergic symptoms

How can CDH26 antibodies be used to explore potential therapeutic applications?

Exploring CDH26 as a therapeutic target using antibody-based approaches:

• Target validation studies:

  • Use blocking antibodies to inhibit CDH26 function in vitro

  • Assess effects on IL-4R signaling and macrophage activation

  • Evaluate impact on epithelial cell functions

  • Compare with genetic knockdown approaches for confirmation

• Therapeutic development strategies:

  • Generate and test therapeutic antibodies targeting functional domains of CDH26

  • Develop antibody-drug conjugates for targeted delivery

  • Explore combination approaches targeting both CDH26 and IL-4R pathways

  • Evaluate tissue-specific delivery approaches

• Preclinical evaluation:

  • Test therapeutic efficacy in animal models of allergic inflammation

  • Compare with siRNA approaches (e.g., Cdh26 siRNA encapsulated lipid nanoparticles)

  • Assess effects on airway eosinophilia, mucus metaplasia, and macrophage activation

  • Evaluate safety and potential off-target effects

• Biomarker development:

  • Use CDH26 antibodies to develop diagnostic assays

  • Evaluate CDH26 expression as a predictive biomarker for response to therapy

  • Develop tissue-based or blood-based assays for patient stratification

What protocols should be used to investigate the molecular mechanisms of CDH26 interaction with STUB1?

Investigating the CDH26-STUB1 interaction requires specialized protocols:

• Protein-protein interaction analysis:

  • Co-immunoprecipitation:

    • Lyse cells in non-denaturing buffers to preserve interactions

    • Immunoprecipitate with anti-CDH26 antibody

    • Probe for STUB1 by Western blotting

    • Perform reciprocal IP with anti-STUB1 antibody

    • Include appropriate controls (IgG IP, input samples)

• Domain mapping studies:

  • Generate truncation mutants of CDH26 and STUB1

  • Express in appropriate cell systems

  • Perform co-IP to identify essential interaction domains

  • Use site-directed mutagenesis to identify critical residues

• Functional consequence assessment:

  • Evaluate effect on IL-4Rα ubiquitination:

    • Express CDH26, STUB1, and IL-4Rα in cells

    • Immunoprecipitate IL-4Rα

    • Probe for ubiquitin by Western blotting

    • Compare conditions with CDH26 knockdown or overexpression

  • Assess IL-4Rα degradation rates:

    • Perform cycloheximide chase experiments

    • Monitor IL-4Rα protein levels over time

    • Compare conditions with altered CDH26 expression

• Structural analysis:

  • Purify recombinant proteins for biophysical studies

  • Perform binding assays to determine affinity constants

  • Consider structural biology approaches (X-ray crystallography, cryo-EM)

How can single-cell approaches be applied to study CDH26 expression in heterogeneous samples?

Applying single-cell technologies to CDH26 research:

• Single-cell RNA sequencing (scRNA-seq):

  • Preparation of single-cell suspensions from relevant tissues

  • Generation of single-cell transcriptome data

  • Identification of cell populations expressing CDH26

  • Correlation with other genes in type 2 inflammation pathways

  • Analysis of cell-specific expression patterns and regulatory networks

• Mass cytometry (CyTOF):

  • Development of metal-conjugated antibodies against CDH26

  • Multiparameter analysis of protein expression

  • Correlation with cell type-specific markers and activation states

  • Clustering analysis to identify distinct cell populations

• Spatial transcriptomics:

  • Combine in situ hybridization for CDH26 with spatial transcriptomics platforms

  • Map CDH26 expression within tissue architecture

  • Correlate with inflammatory microenvironments

  • Identify spatial relationships between CDH26-expressing cells and other cell types

• Single-cell proteomics:

  • Apply antibody-based approaches for single-cell protein analysis

  • Correlate CDH26 protein levels with other signaling molecules

  • Assess heterogeneity in CDH26 expression within defined cell populations

  • Link protein expression to functional states